Attached files
| file | filename |
|---|---|
| EX-21.1 - EXHIBIT 21.1 - Viridian Therapeutics, Inc.\DE | mgen-12312017xex211.htm |
| EX-31.2 - EXHIBIT 31.2 - Viridian Therapeutics, Inc.\DE | mgen-12312017xex312.htm |
| EX-32.1 - EXHIBIT 32.1 - Viridian Therapeutics, Inc.\DE | mgen-12312017xex321.htm |
| EX-31.1 - EXHIBIT 31.1 - Viridian Therapeutics, Inc.\DE | mgen-12312017xex311.htm |
| EX-4.2 - EXHIBIT 4.2 - Viridian Therapeutics, Inc.\DE | mgen-12312017xex42new.htm |
| 10-K - 10-K - Viridian Therapeutics, Inc.\DE | mgen-12312017x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Miragen Therapeutics, Inc.:
We consent to the incorporation by reference in the registration statements (No. 333‑217084) on Form S-3 and (No. 333‑216112) on Form S-8 of Miragen Therapeutics, Inc. of our report dated March 15, 2018 with respect to the consolidated balance sheets of Miragen Therapeutics, Inc. as of December 31, 2017 and 2016, and the related consolidated statements of operations, changed in preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements) which report appears in the December 31, 2017 annual report on Form 10‑K of Miragen Therapeutics, Inc.
/s/ KPMG LLP
Denver, Colorado
March 15, 2018